Inspyr Therapeutics, Inc., clinical-stage pharmaceutical company, focuses on the discovery and development of prodrug cancer therapeutics. The company develops cancer therapeutics for the treatment of solid tumors, including brain, liver, prostate, and other cancers. It focuses on a pipeline of small molecule adenosine receptor modulators, such as A2B antagonists, dual A2A/A2B antagonists, and A2A agonists. The company was formerly known as GenSpera Inc. and changed its name to Inspyr Therapeutics, Inc. in August 2016. Inspyr Therapeutics, Inc. was founded in 2003 and is based in Westlake Village, California.